CytoMed Therapeutics (GDTC) Non-Current Assets (2021 - 2025)

CytoMed Therapeutics has disclosed Non-Current Assets across 5 years of filings, most recently posting $3.3 million for Q4 2025.

• In Q4 2025, Non-Current Assets rose 9.07% year-over-year to $3.3 million; the TTM figure through Dec 2025 stood at $10.0 million (up 14.48% YoY), while the FY2025 annual figure was $4.3 million, up 6.27% from the prior year.
• Non-Current Assets came in at $3.3 million for Q4 2025 at CytoMed Therapeutics, down from $4.3 million in the prior quarter.
• In the past five years, Non-Current Assets ranged from a high of $4.3 million in Q2 2025 to a low of $1.7 million in Q4 2023.
• Average Non-Current Assets over 5 years is $2.8 million, with a median of $2.8 million recorded in 2023.
• Year-over-year, Non-Current Assets decreased 14.54% in 2023 and soared 81.67% in 2024.
• Over 5 years, Non-Current Assets stood at $2.1 million in 2021, then fell by 4.58% to $2.0 million in 2022, then decreased by 14.54% to $1.7 million in 2023, then soared by 81.67% to $3.1 million in 2024, then climbed by 9.07% to $3.3 million in 2025.
• Per Business Quant data, the three most recent Non-Current Assets figures were $3.3 million in Q4 2025, $4.3 million in Q2 2025, and $3.1 million in Q4 2024.